Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin

Clinical Pharmacokinetics

Volumn 43, Issue 14, 2004, Pages 1059-1068

  Sathyan, Gayatri ^a   Dmochowski, Roger R ^b,d   Appell, Rodney A ^c   Guo, Cindy ^a   Gupta, Suneel K ^a  

^a ALZA CORPORATION   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLTOLTERODINE; ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; DEETHYLOXYBUTYNIN; DRUG METABOLITE; OXYBUTYNIN; TOLTERODINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLUID; MALE; NORMAL HUMAN; OPEN STUDY; PH MEASUREMENT; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH JUICE; TABLET;

ADOLESCENT; ADULT; ANTACIDS; BENZHYDRYL COMPOUNDS; CRESOLS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MANDELIC ACIDS; MIDDLE AGED; PHENYLPROPANOLAMINE;

EID: 10044287107     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443140-00008     Document Type: Article

References (16)

1. Public Health Service Agency for Health Care Policy and Re-search (PHSAHCPR). Clinical practice guidelines: urinary incontinence in adults. Washington, DC: US Department of Health and Human Services, 1996
2. Anderson R, Mobley D, Blank B, et al. Once-a-day controlled release versus immediate release oxybutynin chloride in the treatment of urinary urge incontinence. J Urol 1999; 161: 1809-12
3. Nilvebrant L, Andersson KE, Gillberg P, et al. Tolterodine: a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195-207
4. Pahlman I, Gozzi P. Serum protein binding of tolterodine and its major metabolites in humans and several animal species. Biopharm Drug Dispos 1999; 20: 91-9
5. Detrol LA package insert. Kalamazoo (MI): Pharmacia & Upjohn, Dec 2000
6. Eckenhoff B, Theeuwes F, Urquhart J. Osmotically activated dosage forms for rate-controlled drug delivery. Pharm Technol 1981; 5: 35-44
7. Waldman SA, Morganroth J. Effects of food on the bioequivalence of different verapamil sustained-release formulations. J Clin Pharmacol 1995; 35: 163-9
8. Lukkari E, Castern-Kortekangas P, Juhakoski A, et al. Effect of food on the bioavailability of oxybutynin from a controlled release tablet. Eur J Clin Pharmacol 1996; 50: 221-3
9. Ueno K, Kawashima S, Uemoto K, et al. Effect of food on nifedipine sustained-release preparation. DICP 1989; 23: 662-5
10. Sathyan G, Hu W, Gupta SK. Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation. J Clin Pharmacol 2001; 41: 187-92
11. Olsson B, Szamosi J. Food does not influence the pharmacokinetics of a new extended-release formulation of tolterodine for once daily treatment of patients with overactive bladder. Clin Pharmacokinet 2001; 40: 135-43
12. US Pharmacopeia. The official compendia of standards: USP 25-NF 20. 1st ed. Rockville (MD); US Pharmacopeia, 2002
13. Tortara GJ, Anagnostakos NP. The chemical level of organization. In: Tortora GJ, Anagnostakos NP, editors. Principles of anatomy and physiology. 4th ed. San Francisco (CA): Harper & Row, 1984:41
14. Gupta SK, Yih BM, Atkinson L, et al. The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil. J Clin Pharmacol 1995; 35: 1083-93
15. Modi N, Wang B, Hu W, et al. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm Drug Dispos 2000; 21: 23-31
16. Lecaillon JB, Massias P, Schoeller JP, et al. Influence of food on the absorption of metoprolol administered as an OROS delivery system in man. Br J Clin Pharmacol 1985; 19: 245-9S